J Gynecol Oncol.  2009 Dec;20(4):243-245. 10.3802/jgo.2009.20.4.243.

Epstein-Barr virus-transformation of B-cell lines in ovarian cancer patients: feasibility of genomic storage for unlimited use

• Kong SY
• Kang S

• KMID: 2288590
• DOI: http://doi.org/10.3802/jgo.2009.20.4.243

Abstract

OBJECTIVE
The aim of the current study is to test whether immortalized B-lymphocyte cell line via Ebstein-Barr virus (EBV) transformation is feasible and can be an unlimited source of genome wide study.
METHODS
We obtained peripheral whole blood from 5 ovarian cancer patients and immortalized the B-cell lines using EBV transformation. The success rate was analyzed and the bio-identity of the genome was performed using human leukocyte antigen (HLA) identity test.
RESULTS
EBV transformation was successful in all 5 cases (95% confidence interval, 46.3% to 100%). After cryopreservation of EBV-transformed B-cell lines and subsequent thawing, we observed that all cell lines were viable and proliferative. To check bio-identity, HLA-A, B, and DR were tested between the genome of the original samples and the transformed samples. The HLA typing revealed that all observed HLA-A, B, and DR type was identical in 5 cases before and after EBV-transformation.
CONCLUSION
The current results suggest that EBV-transformation of peripheral blood is an efficient tool in genome banking. The EBV-transformed B-cell lines may be a valuable resource of genome in multi-center translational research by the Korean Gynecologic Oncology Group.

Keyword

Genomics; Epidemiology; DNA storage; EBV transformation; Cryopreservation

MeSH Terms

B-Lymphocytes
Cell Line
Cryopreservation
Genome
Genomics
Herpesvirus 4, Human
Histocompatibility Testing
HLA-A Antigens
Humans
Leukocytes
Ovarian Neoplasms
Viruses
HLA-A Antigens

Reference

1. Taramelli R, Acquati F. The human genome project and the discovery of genetic determinants of cancer susceptibility. Eur J Cancer. 2004. 40:2537–2543.

2. Hopkinson I, Mackay J. The clinical impact of the Human Genome Project: inherited variants in cancer care. Ann Oncol. 2002. 13:Suppl 4. 105–107.

3. Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet. 2003. 33:Suppl. 238–244.

4. Strausberg RL, Simpson AJ, Wooster R. Sequence-based cancer genomics: progress, lessons and opportunities. Nat Rev Genet. 2003. 4:409–418.

5. Kim SY, Hahn WC. Cancer genomics: integrating form and function. Carcinogenesis. 2007. 28:1387–1392.

6. Harkin DP. Genomics and the impact of new technologies on the management of colorectal cancer. Oncologist. 2006. 11:988–991.

7. Weber BL. Cancer genomics. Cancer Cell. 2002. 1:37–47.

8. Zhang W, Laborde PM, Coombes KR, Berry DA, Hamilton SR. Cancer genomics: promises and complexities. Clin Cancer Res. 2001. 7:2159–2167.

9. Godard B, Schmidtke J, Cassiman JJ, Ayme S. Data storage and DNA banking for biomedical research: informed consent, confidentiality, quality issues, ownership, return of benefits. A professional perspective. Eur J Hum Genet. 2003. 11:Suppl 2. S88–S122.

10. Bass H, Darke C. Improved efficiency of EBV transformation of B-lymphocytes. Cell Prolif. 2004. 37:443–444.

11. Bass H, Walters R, Darke C. Provision of Epstein-Barr virus-transformed B-cell lines in a routine tissue typing laboratory: practicalities and applications. Eur J Immunogenet. 2004. 31:87–92.

12. Austin MA, Ordovas JM, Eckfeldt JH, Tracy R, Boerwinkle E, Lalouel JM, et al. Guidelines of the National Heart, Lung, and Blood Institute Working Group on Blood Drawing, Processing, and Storage for Genetic Studies. Am J Epidemiol. 1996. 144:437–441.

13. Hayes RB, Smith CO, Huang WY, Read Y, Kopp WC. Whole blood cryopreservation in epidemiological studies. Cancer Epidemiol Biomarkers Prev. 2002. 11:1496–1498.

14. Penno MB, Pedrotti-Krueger M, Ray T. Cryopreservation of whole blood and isolated lymphocytes for B-cell immortalization. J Tissue Cult Methods. 1993. 15:43–48.